Indian Medtechs Call US Tariffs A Challenge To Growth And Seek Reciprocal Regulatory Access

Indian Medtech Firms Want Level Playing Field On Tariffs And Action On US Non-Tariffs Barriers

India’s medical technology industry is raising the alarm over steep new US tariffs on imported medical devices. It argues for structural change to address “unequal regulatory access” and non-tariff barriers.

Indian medtech industry leaders now argue that the potential benefits may be limited if systemic trade imbalances and regulatory hurdles are not addressed.
Key Takeaways

· AiMeD calls for tariff parity and reciprocal regulatory access as US imposes import duty of 27%, reduced to 10% for 90 days.

· Industry says Indian customs duties, among the lowest globally for medical devices, “must be addressed.”.

· Non-tariff barriers such as high US registration fees and lengthy clinical trials are “real roadblocks to Indian medtech exports” and far outweigh the impact of tariffs.

India’s medtech sector is voicing strong concerns about US President Trump’s 27% reciprocal tariff on imports from India. The tariff...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Asia

FDA Greenlights Expanded Use Of Boston Scientific’s Pulse Field Ablation System

 

A recent approval from the US FDA allowing Boston Scientific to broaden its labeling for its pulse field ablation system means more patients with one type of AFib will have access to a promising new treatment.

South Korean Health Ministry Sees Benefits Of Pre-Regulatory Review

 
• By 

A system of pre-regulatory review consultations for innovative drugs and devices in South Korea has contributed to the accelerated development of such products.

FDA Blocks Some Olympus Endoscopes From Entering US

 

After multiple warning letters and safety communications, the US FDA has decided to block the import of certain endoscopes from Olympus. In total, the agency’s action pertains to 58 device models manufactured by the Japanese firm used in urinary, respiratory, abdominal and pelvic procedures.

New EU Rules Limit Chinese Participation In Medtech Procurement

 

From June 30, new European Commission rules will attempt to redress an imbalance in medtech trade between the EU and the People’s Republic of China.

More from Medtech Insight

Execs On The Move: July 7–11, 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

EU Authorities Unite In Call For Urgent Overhaul Of Medtech Regulations

 

EU member states have issued a consensus statement on the urgent need to build momentum to tackle governance and centralization issues as part of much-needed reform of the EU medtech regulatory system.

‘Eyes – A Window Into The Heart’: Retinal AI Tool Predicts Future Risk Of Heart Attack And Stroke

 

A deep-learning AI-based retinal image scanning tool can predict the risk of cardiovascular events over a 10-year period with 70% accuracy. The test is comparable to routine GP health checks, researchers from the University of Dundee have shown.